Similar results were found in another study of 22 patients with MET exon 14 skipping NSCLC treated with ICI therapy (ORR 17%, 95% CI 6-36, median PFS 1.9 months, 95% CI 1.7-2.7) (49). This evidence concerns the gene MET and non-small cell lung carcinoma.